ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

GLP1R

glucagon like peptide 1 receptor · also GLP-1R · Glucagon receptor family

41 programs in company-led studies act on GLP1R, from 26 companies: 18 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (22 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
TirzepatideruleEli Lillyagonistphase 47219 runningGIPRChEMBL
SemaglutideruleNovo Nordiskagonistphase 417018 running–NCIt
LiraglutideruleNovo Nordiskagonistphase 41165 running–ChEMBL
dulaglutideruleEli Lillyagonistphase 4471 running–NCIt
zenagamtideNovo Nordiskagonistphase 33526 runningCALCRa judged reading
orforglipronruleEli Lillyagonistphase 35017 running–the studies' text
berobenatidePfizeragonistphase 32317 running–the company's pipeline
brenipatideEli Lillyagonistphase 31916 runningGIPRa judged reading
UBT251The United Laboratories Internationalagonistphase 31212 runningGCGR, GIPRa judged reading
retatrutideruleEli Lillyagonistphase 33311 runningGCGR, GIPRChEMBL
survodutideBoehringer Ingelheimagonistphase 33510 runningGCGRthe company's pipeline
mazdutideruleInnovent Biologicsagonistphase 3279 running–the studies' text
bofanglutideruleGan & Lee Pharmaceuticalsagonistphase 3259 running–the studies' text
olatorepatideHansoh Pharmaceutical Groupagonistphase 3127 runningGIPRa judged reading
enicepatideHoffmann-La Rocheagonistphase 3107 runningGIPRa judged reading
VK2735ruleViking Therapeuticsagonistphase 385 runningGIPRthe studies' text
MDR-001ruleMindRank AIagonistphase 365 running–the studies' text
DR10624ruleHuadong Medicineagonistphase 364 runningGCGRthe studies' text
SafiglipronJiangsu HengRui Medicine–phase 3193 running–the company's pipeline
efpeglenatideruleHanmi Pharmaceuticalagonistphase 3131 running–ChEMBL
avexitideruleAmylyx Pharmaceuticals–phase 321 running–NCIt
edaglutide alfaCSPC Pharmaceutical Groupagonistphase 3110 running–a judged reading
AZD9550AstraZenecaagonistphase 275 runningGCGRa judged reading
BI 3034701Boehringer Ingelheimagonistphase 264 runningGIPR, NPY2Rthe company's pipeline
HRS-4729Jiangsu HengRui Medicine–phase 254 runningGCGR, GIPRthe company's pipeline
NNC0519-0130Novo Nordiskagonistphase 2111 runningGIPRa judged reading
naperiglipronEli Lillyagonistphase 2101 running–a judged reading
NA-931ruleBiomed Industriesagonistphase 231 runningGIPR, IGF1the studies' text
TE-8105ruleImmunworkagonistphase 221 running–the studies' text
danuglipronrulePfizeragonistphase 2180 running–ChEMBL
efinopegdutideJohnson & Johnsonagonistphase 2150 runningGCGRa judged reading
RGT001-075ruleRegor Pharmaceuticalsagonistphase 230 running–the studies' text
TQF3250Sino Biopharmaceuticalagonistphase 133 running–the company's pipeline
IBI3042ruleInnovent Biologicsagonistphase 122 running–the studies' text
PF-08642534Pfizeragonistphase 121 running–the company's pipeline
BLX-7006ruleBiolexis Therapeuticsagonistphase 111 running–the studies' text
PF-08656795Pfizeragonistphase 111 running–the company's pipeline
XTL6001ruleShanghai Xitaili Biomedicine Technologyagonistphase 111 running–the studies' text
dapiglutideruleZealand Pharmaagonistphase 140 running–the studies' text
BMF-650ruleBiomea Fusionagonistphase 110 running–the studies' text
CagriSema ANovo Nordiskagonistphase 110 runningCALCRa judged reading

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.